AstraZeneca is defending itself.
On Monday, the laboratory whose vaccine has been suspended in several countries after the emergence of blood clots in patients, published results related, according to him, to phase III clinical trials conducted in the United States.
According to these findings, its serum against Covid-19 is 80% effective against Covid-19 in the elderly and does not increase the risk of clots in the blood.
The vaccine is 79% effective in preventing symptomatic Covid-19 in the general population and 100% in preventing severe forms of the disease and hospitalization, also assures the laboratory.
No increased risk of thrombosis
Several countries have given up on prescribing it to the elderly due to a lack of data on the elderly in previous trials.
This month several countries have suspended its use for fear that it could cause blood clots, sometimes fatal.
Phase III clinical trials implemented by AstraZeneca and the University of Oxford have been carried out on 32,449 participants, two-thirds of which received an injection of the vaccine, the firm said in a statement.
20% of them were over 65 and 60% had health problems associated with higher risks of developing a severe form of Covid, such as diabetes, obesity or heart problems.
The trials did not find an increased risk of thrombosis among participants who received at least one dose, according to the release.
